A recent survey found that one in eight U.S. adults has tried a GLP-1 drug. (Think Wegovy or Zepbound.) The drugs can be effective against obesity and other indications, but high prices and patchy insurance coverage have left them out of reach for many. What would it take to expand access?
↧